Denis Chem Lab Limited has received multiple disclosures under the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, regarding significant shareholding changes. The latest disclosure under Regulation 29(1) from Varun Daga Family Trust confirms the coordinated acquisition structure that resulted in aggregate holdings of 9.64% in the company.

Varun Daga Family Trust Disclosure

Varun Daga Family Trust, acting as trustee through Varun Daga, filed a disclosure under Regulation 29(1) on March 30, 2026, confirming their substantial acquisition in Denis Chem Lab Limited. The trust acquired 2,67,499 equity shares representing 1.93% of the company's paid-up equity share capital through an off-market transaction completed on March 27, 2026.

Coordinated Acquisition Structure

The acquisition involved a coordinated effort between Varun Daga Family Trust as the acquirer and persons acting in concert including Shreans Daga Family Trust and Kanchan Daga. The aggregate acquisition resulted in total holdings of 13,37,498 equity shares representing 9.64% of the company's share capital.

Previous Holdings and Transaction Details

According to the regulatory disclosure, Varun Daga Family Trust had no previous holdings in Denis Chem Lab Limited before this acquisition. The trust's holdings increased from nil to 2,67,499 equity shares through the off-market transaction, establishing their 1.93% stake in the company.

Company Share Capital Structure

Denis Chem Lab Limited's equity share capital structure remained unchanged throughout these transactions. The company maintains its listing on BSE Limited with consistent share capital parameters as confirmed in the regulatory disclosures.

Regulatory Compliance

All disclosures were made in strict accordance with SEBI regulations. The Varun Daga Family Trust's Regulation 29(1) disclosure established the substantial shareholding acquisition through coordinated action with persons acting in concert. All parties confirmed they do not belong to the promoter or promoter group category, and all transactions involved only equity shares carrying voting rights with no encumbrances.

Denis chem lab Limited, a manufacturer of parenteral products, announced its unaudited financial results for the quarter ended December 31, 2025, showcasing strong operational performance across key financial metrics. The Board of Directors approved these results during their meeting held on February 14, 2026, under Regulation 33 of SEBI (LODR) Regulations, 2015.

Financial Performance Highlights

The company delivered impressive financial results for Q3FY26, with significant improvements in profitability and revenue growth. Denis Chem Lab demonstrated robust business momentum during the quarter, reflecting effective operational management and market positioning.

Nine-Month Cumulative Performance

For the nine months ended December 31, 2025, Denis Chem Lab maintained strong performance momentum with consistent growth across revenue and profitability parameters.

Board Meeting and Regulatory Compliance

The Board of Directors meeting commenced at 10:00 a.m. and concluded at 12:45 p.m. on February 14, 2026. The results were submitted under Regulation 33 and other applicable provisions of SEBI (LODR) Regulations, 2015. Managing Director Himanshu C. Patel (DIN: 00087114) signed the regulatory filings, confirming compliance with all statutory requirements.

Operational Efficiency and Business Profile

Denis Chem Lab Limited operates exclusively in manufacturing and sales of transfusion solutions in bottles, maintaining focus on its core business segment. The company has no subsidiaries or associates, operating as a standalone entity. The financial results were prepared in accordance with Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Companies Act, 2013.

The company maintains a paid-up equity share capital of ₹1,387.67 lakh with face value of ₹10 per share, remaining unchanged from previous periods. The audit committee reviewed these financial results before Board approval, with statutory auditors issuing an unmodified opinion on the quarterly results.